Cargando…
Genome-wide methylation patterns predict clinical benefit of immunotherapy in lung cancer
BACKGROUND: It is crucial to unravel molecular determinants of responses to immune checkpoint blockade (ICB) therapy because only a small subset of advanced non-small cell lung cancer (NSCLC) patients responds to ICB therapy. Previous studies were concentrated on genomic and transcriptomic markers (...
Autores principales: | Kim, Jeong Yeon, Choi, Jung Kyoon, Jung, Hyunchul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410160/ https://www.ncbi.nlm.nih.gov/pubmed/32762727 http://dx.doi.org/10.1186/s13148-020-00907-4 |
Ejemplares similares
-
Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity
por: Kim, Kwoneel, et al.
Publicado: (2020) -
Genome-wide DNA methylation signature predict clinical benefit of bevacizumab in non-small cell lung cancer
por: Li, Butuo, et al.
Publicado: (2022) -
Genome-wide analysis of DNA methylation patterns in horse
por: Lee, Ja-Rang, et al.
Publicado: (2014) -
Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer
por: Hwang, Sohyun, et al.
Publicado: (2020) -
DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load
por: Jung, Hyunchul, et al.
Publicado: (2019)